Market Overview: GLP-1 Agonists and the Obesity Market

Market Overview: GLP-1 Agonists and the Obesity Market

Introduction to GLP-1 Agonists GLP-1 agonists have been pivotal in the pharmaceutical market for nearly two decades, beginning with the FDA approval of AstraZeneca’s Byetta in 2005. Since then, the landscape has seen numerous entries and exits, leaving Novo Nordisk...